[go: up one dir, main page]

PE20010701A1 - ONCOLITIC COMBINATIONS FOR THE TREATMENT OF CANCER - Google Patents

ONCOLITIC COMBINATIONS FOR THE TREATMENT OF CANCER

Info

Publication number
PE20010701A1
PE20010701A1 PE2000001206A PE0012062000A PE20010701A1 PE 20010701 A1 PE20010701 A1 PE 20010701A1 PE 2000001206 A PE2000001206 A PE 2000001206A PE 0012062000 A PE0012062000 A PE 0012062000A PE 20010701 A1 PE20010701 A1 PE 20010701A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
cancer
carcinoma
treatment
Prior art date
Application number
PE2000001206A
Other languages
Spanish (es)
Inventor
Edward C R Smith
Douglas Wade Beight
Jerome Herbert Fleisch
Beverly Ann Teicher
Jason Scott Sawyer
William Thomas Mcmillen
Roger Stuart Benjamin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010701A1 publication Critical patent/PE20010701A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE a)UN ANTAGONISTA DE LEUCOTRIENO (LTB4) DE FORMULA I, X ES UN HETEROCICLO DE 5 MIEMBROS CON 1-4 HETEROATOMOS, BICICLO; Y ES UN ENLACE O UN GRUPO DIVALENTE CON 1-9 ATOMOS; Y2, Y3 SON CH2, O, S,; Z ES UN GRUPO ACIDICO; R1 ES ALQUILO C1-C6, ARILO, CICLOALQUILO C2-C10, ENTRE OTROS; R2 ES H, HALOGENO, HALOALQUILO C1-C10, ALCOXI C1-C10, ENTRE OTROS; R3 ES H, HALOGENO, ALQUILO C1-C10, ARILO, ENTRE OTROS; R4 ES ALQUILO C1-C4, CICLOALQUILO C3-C4, CH2(1-7)(CICLOALQUILO C3-C4), ENTRE OTROS; M ES 0-6; UN COMPUESTO PREFERIDO ES 2-[2-PROPIL-3-[3-[2-ETIL-5-HIDROXI-4-(4-FLUOROFENIL)FENOXI]PROPOXI]FENOXI ACIDO BENZOICO Y b)UN AGENTE ANTICANCEROSO 2`,2'-DIFLUORONUCLEOSIDO DE FORMULA II, DONDE R1 ES H, -COR5; R2 ES UN GRUPO a, b; X ES N, CR4; R3 ES H, ALQUILO C1-C4, COR5; R4 ES H, ALQUILO C1-C4, AMINO, Br, ENTRE OTROS; R5 ES H, ALQUILO C1-C4; UN COMPUESTO PREFERIDO ES GEMCITABINA HCl, 2'-DEOXI-2',2'-DIFLUOROCITIDINA MONOCLORHIDRATO (ß-ISOMERO). LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER, CARCINOMA DE MAMA, CARCINOMA DE VEJIGA, CARCINOMA COLORECTAL, CARCINOMA ESOFAGICOREFERS TO A COMPOSITION INCLUDING a) A LEUCOTRIENE ANTAGONIST (LTB4) OF FORMULA I, X IS A 5-MEMBER HETEROCYCLE WITH 1-4 HETEROATOMS, BICYCLE; AND IT IS A LINK OR A DIVALENT GROUP WITH 1-9 ATOMS; Y2, Y3 ARE CH2, O, S ,; Z IS AN ACIDIC GROUP; R1 IS C1-C6 ALKYL, ARYL, C2-C10 CYCLOALKYL, AMONG OTHERS; R2 IS H, HALOGEN, C1-C10 HALOALKYL, C1-C10 ALCOXY, AMONG OTHERS; R3 IS H, HALOGEN, C1-C10 ALKYL, ARYL, AMONG OTHERS; R4 IS C1-C4 ALKYL, C3-C4 CYCLOALKYL, CH2 (1-7) (C3-C4 CYCLOALKYL), AMONG OTHERS; M IS 0-6; A PREFERRED COMPOUND IS 2- [2-PROPYL-3- [3- [2-ETHYL-5-HYDROXY-4- (4-FLUOROPHENYL) PHENOXY] PROPOXY] PHENOXY BENZOIC ACID AND b) AN ANTI-CANCER AGENT 2`, 2 ' -DIFLUORONUCLEOSIDE OF FORMULA II, WHERE R1 IS H, -COR5; R2 IS A GROUP a, b; X IS N, CR4; R3 IS H, C1-C4 ALKYL, COR5; R4 IS H, C1-C4 ALKYL, AMINO, Br, AMONG OTHERS; R5 IS H, C1-C4 ALKYL; A PREFERRED COMPOUND IS GEMCITABIN HCl, 2'-DEOXI-2 ', 2'-DIFLUOROCYTIDINE MONOCLORHYDRATE (ß-ISOMER). THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF CANCER, BREAST CARCINOMA, BLADDER CARCINOMA, COLORECTAL CARCINOMA, ESOPHAGEAL CARCINOMA

PE2000001206A 1999-11-11 2000-11-10 ONCOLITIC COMBINATIONS FOR THE TREATMENT OF CANCER PE20010701A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11

Publications (1)

Publication Number Publication Date
PE20010701A1 true PE20010701A1 (en) 2001-07-07

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001206A PE20010701A1 (en) 1999-11-11 2000-11-10 ONCOLITIC COMBINATIONS FOR THE TREATMENT OF CANCER

Country Status (22)

Country Link
EP (1) EP1231938A2 (en)
JP (1) JP2003513916A (en)
KR (1) KR20020069512A (en)
CN (1) CN1390139A (en)
AR (1) AR032432A1 (en)
AU (1) AU778829B2 (en)
BR (1) BR0015490A (en)
CA (1) CA2391416A1 (en)
CZ (1) CZ20021551A3 (en)
EA (1) EA200200545A1 (en)
HK (1) HK1050132A1 (en)
HU (1) HUP0204449A3 (en)
IL (1) IL148579A0 (en)
MX (1) MXPA02004733A (en)
NO (1) NO20022245L (en)
NZ (1) NZ517667A (en)
PE (1) PE20010701A1 (en)
PL (1) PL355172A1 (en)
SK (1) SK6492002A3 (en)
TR (1) TR200201245T2 (en)
WO (1) WO2001034137A2 (en)
ZA (1) ZA200202822B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Cancer combination therapy
EP1326605A4 (en) * 2000-05-09 2004-03-17 Univ Creighton USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP2007536343A (en) 2004-05-05 2007-12-13 ノボ ノルディスク アクティーゼルスカブ Phenoxyacetic acid derivatives as PPAR agonists
ATE515494T1 (en) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc NEW COMPOUNDS, THEIR PRODUCTION AND USE
CN1302782C (en) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 Jixitabing hydrochloride solution type injection agent
EP1899302B1 (en) 2005-06-30 2011-10-19 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
ES2386734T3 (en) 2005-12-22 2012-08-28 High Point Pharmaceuticals, Llc Phenoxyacetic acids as activators of PPAR-DELTA
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
WO2008044729A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivative
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (en) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclic compounds as pesticides
EP2914587A1 (en) 2012-10-31 2015-09-09 Bayer CropScience AG Novel heterocyclic compounds as pest control agents
CN103319466B (en) * 2013-07-04 2016-03-16 郑州大学 Containing the 1,2,3-triazoles-dithiocarbamates compound of tonka bean camphor parent nucleus, preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
CA2391416A1 (en) 2001-05-17
JP2003513916A (en) 2003-04-15
EP1231938A2 (en) 2002-08-21
AR032432A1 (en) 2003-11-12
TR200201245T2 (en) 2004-08-23
HK1050132A1 (en) 2003-06-13
NO20022245D0 (en) 2002-05-10
PL355172A1 (en) 2004-04-05
NZ517667A (en) 2004-05-28
SK6492002A3 (en) 2003-09-11
HUP0204449A2 (en) 2003-04-28
IL148579A0 (en) 2002-09-12
AU778829B2 (en) 2004-12-23
CZ20021551A3 (en) 2003-02-12
WO2001034137A2 (en) 2001-05-17
HUP0204449A3 (en) 2006-02-28
WO2001034137A3 (en) 2002-02-14
MXPA02004733A (en) 2002-08-30
AU1599001A (en) 2001-06-06
CN1390139A (en) 2003-01-08
NO20022245L (en) 2002-07-09
KR20020069512A (en) 2002-09-04
BR0015490A (en) 2002-07-09
ZA200202822B (en) 2003-09-23
EA200200545A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
PE20010701A1 (en) ONCOLITIC COMBINATIONS FOR THE TREATMENT OF CANCER
CY1124503T1 (en) BOROPHTHALIDES FOR THERAPEUTIC USE
PE20001483A1 (en) OXAMIC ACIDS AND DERIVATIVES AS LIGANDS OF THYROID RECEPTORS
SE9704404D0 (en) New compounds
TR200000837A2 (en) Process and intermediates to prepare anti-cancer compositions.
PT1041072E (en) DIOXOCYCLOPENTIL HYDROXYM ACIDS
PE20060427A1 (en) PIRAZOLE DERIVATIVES AS GLUCAGON BINDING INHIBITORS AND COMPOSITIONS
PE20080706A1 (en) ARYLMIDAZOLONES AND ARYLTHRIAZOLONES SUBSTITUTED AS VASOPPRESSIN RECEPTOR INHIBITORS
PE20091527A1 (en) PYRIDAZINONE DERIVATIVES
PE20061303A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING OXAPROZIN
AR040971A1 (en) PIRIMID COMPOUNDS THAT HAVE ANTIPROLIFERATIVE ACTIVITY
MA27040A1 (en) SUBSTITUTED NUCLEOSIDES IN 4 '
CY1105160T1 (en) OXAZOLE DERIVATIVES WITH CARBOXYLIC ACID SUBSTITUENTS FOR USE AS PPAR-α AND -γ ACTIVATORS FOR THE TREATMENT OF DIABETES
CY1108367T1 (en) PAINYL-CARBOXAMID COMPOUNDS USEFUL FOR PANTS
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
SE9700661D0 (en) New compounds
TR200003383T2 (en) Compositions for the treatment of HIV and other virus infections.
MY129310A (en) C-4 carbonate taxanes
SE9602286D0 (en) New compounds
BR0206552A (en) Use of at least one quinoline, quinoline, and pharmaceutical composition
PE20001083A1 (en) MONONITRATE DERIVATIVES OF ISOSORBIDE
DE69919349D1 (en) PIPERIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES
ATE269851T1 (en) BENZIMIDAZOLE DERIVATIVES
ATE340572T1 (en) BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA
DE60127535D1 (en) PREVENTIVE OR THERAPEUTIC AGENTS AGAINST GASTRIC OR OESOPHAGEAL REGURGITATION

Legal Events

Date Code Title Description
FD Application declared void or lapsed